BCAL Diagnostics develops blood test to evaluate breast cancer

BCAL Diagnostics is developing the BREASTEST Monitor blood test intended to assist in evaluating women for local breast cancer recurrence after treatment. BREASTEST Monitor development used over 450 samples; algorithm tested on 100 samples, with 23 recurrences and 77 controls. BCAL aims to introduce the test as imaging adjunct, with further development for standalone use targeted. Credit: NMK-Studio / Shutterstock.com. Australian healthcare company BCAL Diagnostics is developing the BREASTEST Monitor blood test intended to assist in evaluating women for local breast cancer recurrence after treatment. The company stated that local recurrence in the breast or lymph nodes can occur in…

Source: Medical Device Network